|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||147.43 kg/mol|
Pidilizumab (formerly CT-011) is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases. Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, but this is currently uncertain. Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells.
It had encouraging results by 2011 from phase II clinical trials for diffuse large B-cell lymphoma. A phase II open-label study in combination for relapsed follicular lymphoma found good results compared to usual response rates. An add-on trial for multiple myeloma is ongoing.
- Westin; et al. (2014). "Safety and Activity of PD1 Blockade by Pidilizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: a Single Group, Open-label, Phase 2 Trial". Lancet Oncol. 15: 69–77. PMC . PMID 24332512. doi:10.1016/S1470-2045(13)70551-5.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Pidilizumab, American Medical Association- needs login.
- Teva Invests $19M More in CureTech After Positive Phase II DLBCL Data. Sept 2011
- "Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2015-08-22.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|